Xenon Pharmaceuticals XENE Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's other income (expense)?
- Xenon Pharmaceuticals (XENE) reported other income (expense) of $7.46M in Q1 2026.
- How has Xenon Pharmaceuticals's other income (expense) changed year-over-year?
- Xenon Pharmaceuticals's other income (expense) decreased by 8.2% year-over-year, from $8.12M to $7.46M.
- What is the long-term trend for Xenon Pharmaceuticals's other income (expense)?
- Over 3 years (2022 to 2025), Xenon Pharmaceuticals's other income (expense) has grown at a 93.5% compound annual growth rate (CAGR), from $3.89M to $28.18M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.